What's Going On With Capricor Therapeutics Stock Monday?
Capricor Therapeutics (CAPR) shares top-line HOPE-3 extension data for Deramiocel in DMD ahead of its Nov 22 FDA PDUFA date.
Share
Why It Matters
Capricor shared new test results for a Duchenne muscle disease treatment. The FDA will decide on approval by late November, so watch how doctors react.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.